Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Randomized, Multicenter, Phase III Study, Comparing Standard Chemotherapy to Standard Combination of Endocrine Therapy With Abemaciclib as Initial Metastatic Treatment Among Patients With Visceral Metastasis of ER+ HER2-breast Cancer, High Burden Disease

NCT04158362 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT04158362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04158362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Randomized, Multicenter, Phase III Study, Comparing Standard Chemotherapy to Standard Combination of Endocrine Therapy With Abemaciclib as Initial Metastatic Treatment Among Patients With Visceral Metastasis of ER+ HER2-breast Cancer, High Burden Disease
Lead sponsor
UNICANCER
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 11, 2020
Completion date
June 30, 2032
Enrollment
180 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cancer metastatic